A previously healthy 54-year-old Caucasian female was admitted to the hospital because of the diagnosis of common B-cell acute lymphoblastic leukemia (ALL), associated with t(9;22) chromosomal translocation. She was commenced on induction chemotherapy with daunorubicin, vincristine and prednisone, according to the LAL-2000 protocol for ALL proposed by Italian multicentre group GIMEMA. On day þ 15 daily routine examination of the patient's vital parameters, revealed an oxygen saturation measured by pulse oximeter of 88%, with PaO 2 of 58 mmHg on room air. The patient was afebrile, and asymptomatic. Neither oral nor genital herpetic lesions were observed on physical examination. Full blood count revealed grade III neutropenia. A chest roentgenogram showed no abnormalities of the lung parenchyma. A highresolution computed tomography (HRCT) scan revealed the presence of bilateral airspace consolidation and ground glass pattern in the lower regions of the lungs (Figure 1a ). Bronchofibroscopy with brochoalveolar lavage was performed and endobronchial findings included airway edema and purulent secretions. No bacterial, or fungal, or viral pathogens were isolated. Neither Pneumocystis carinii infection nor leukemic cells were detected on cytological examination. CMV antigenemia and the search for Legionella antigen in urine were negative. Both tubercolin skin test and quantiferon test resulted negative. The chemotherapy was interrupted and the patient was treated empirically with piperacillin/tazobactam, for 3 days and then with carbapenem and vancomycin. Despite this treatment the patient showed evidence of respiratory deterioration, being arterial PaO 2 of 48 mmHg on room air, but remaining afebrile. The conventional chest X-ray (CXR) showed lung opacification in the right lower and central lobe and in the left lower lobe. Neither pleural effusions nor atelectasis were seen (Figure 1b) . The CT scan showed worsening of the pneumonia pattern in multifocal patchy consolidations and ground glass opacities (Figure 1c ). Intravenous amphotericin B and high-dose cotrimoxazole were introduced and a second bronchoalveolar lavage was performed on day þ 21, but again with negative cultural results for bacterial and fungal agents. Lung biopsy performed by thoracotomy on day þ 29 showed a nonspecific fibroproliferative pattern and tissue necrosis. On day þ 31 the finding of herpes simplex virus-1 (HSV-1) isolation from the second patient's brocholaveolar lavage fluid was obtained and therapy with acyclovir (10 mg/kg every 8 h) was immediately started, in addition to antibiotic prophylaxis with amoxicillin/clavulanate and fluconazole. The patient showed an initial deterioration in her pulmonary function and needed 48 h of pulmonary support with noninvasive ventilation in intensive unit care. Then, the patient's respiratory parameters gradually improved and oxygen saturation returned to normal values after 3 weeks. On day þ 42 conventional chest radiograph cleared and CT scan showed almost complete resolution of the ground glass and consolidation pattern (Figure 1d) . Following her initial course of acyclovir she continued on a prophylactic oral dose of valacyclovir during completion of induction treatment. The patient obtained complete hematological remission and underwent consolidation chemotherapy, and then was commenced on imatinib therapy without further complications.
Reactivation of latent HSV is the most common viral infection in patients during the profound neutropenia that occurs during remission induction in patients with lymphoma and acute leukemia and during the conditioning phase of bone marrow transplantation (BMT). Symptomatic HSV infection occurs in the first 2-3 weeks after BMT, when mucosal damage is maximal as a consequence of the radiotherapy and chemotherapy used for conditioning. 1 The most common clinical manifestation is oral ulceration, often necrotic and long lasting, which may complicate with oesophagitis, but reactivation of genital HSV may also occur, although less frequently. HSV-1 pneumonitis may follow oral or genital HSV either from contiguous spread from the oropharynx, or hematogenous dissemination. Prophylaxis of HSV infection with acyclovir has contributed to the decreased prevalence of HSV pneumonitis to less than 2% of BM recipients. 1 In the management of febrile neutropenic patients emphasis is placed on the diagnosis and treatment of bacterial and fungal infection, while investigation for viruses are often omitted because the yield is poor and treatment options limited. Systemic infections and disease due to cytomegalovirus, for example, are uncommon causes of fever in neutropenic patients with the exception of those who have undergone BMT. Thus, antiviral drugs are indicated only if there is clinical or laboratory evidence of viral disease. 2 Wirth et al 3 described a patient with ALL presenting three localized episodes of HSV-1 infection during the course of standard chemotherapy, each of which had been successfully treated with acyclovir; then the patient developed a lethal systemic HSV-1 infection documented by autoptic diffuse macroscopic infiltration of liver, colon and oesophagus, emphasizing the severe pathogenic potential of HSV even in neutropenic patients out of BMT setting. The possible, although rare occurrence of HSV pneumonia should be also considered in neutropenic hematological patients undergoing standard chemotherapy, with 'suggestive' radiographic findings, not improving after conventional antibiotic and/or antifungal treatment. The isolation of HSV from BAL fluid should be pursued, and more than one attempt of viral isolation from different specimens obtained by repeated BAL procedures could be advised in selected patients for accurately diagnosing HSV pneumonia. The radiographic findings, first detected in our patient only on HRCT and then also on CXR, raise the important issue of the differential diagnosis among the possible causes of pulmonary infiltrates in leukemic patients. Umans et al 4 recently described the conventional chest radiographic pattern in a wellcharacterized series of 14 patients, most of whom affected with hematologic diseases, and selected on the basis of a microbiologically proven mono-infection with HSV. The main recurrent radiographic finding was represented by bilateral lung opacification, predominantly lobar, or diffuse, with a pattern that was partly airspace consolidation and partly interstitial (mixed type), while atelectasis and pleural effusions resulted uncommon. These findings have been confirmed and extended by Aquino et al 5 who described, in a series of 23 patients with HSV-1 pneumonia, the presence of patchy ground glass opacities and consolidation with a predominantly diffuse distribution on conventional chest radiographs. The CT findings available in 8 of these patients showed multifocal segmental ground glass opacities and additional focal areas of consolidation, with a scattered distribution. The radiographic findings in our patient are thus consistent with those commonly reported in association with HSV-1 pneumonia, although they are clearly not specific, being suggestive for a variety of other conditions, including either infectious (Pneumocystis carinii pneumonia) or noninfectious diseases (cryptogenic-organizing pneumonia, pulmonary chronic graft-versus-host disease, adult acute respiratory distress syndrome, and leukemic pulmonary infiltrates). 6 The definite diagnosis of HSV pneumonia can only be established on the basis of culture of material obtained by BAL as well as of blood in the case of hematogenous viral dissemination. However, it should be noted that HSV-1 isolation from BAL fluid was successful only on the second BAL specimen. The difficulty inherent with viral isolation was also exemplified by two previous case reports. In the former, a patient with acute myeloid leukemia presented with HSV-1 pneumonia, as a result of HSV-1 primary infection. The diagnosis of HSV pneumonia was suggested by the diffuse appearance of the pneumonia on CXR, the isolation of HSV-1 from blood and the response to antiviral therapy, while the isolation of HSV-1 from the BAL was unsuccessful. 7 Similarly, in the latter case, the diagnosis of late-onset HSV pneumonia after allogeneic BMT for chronic myeloid leukemia was suggested by the detection of viral sequences in the peripheral blood and by the good response to acyclovir, but, again, the HSV could not be isolated from the BAL fluid. 8 We report here the occurrence of HSV-1 pneumonia in a patient with B-cell common ALL. The diagnosis relies on the radiological appearance of pneumonia on either CXR or HRCT, the isolation of HSV-1 from BAL concomitant with the absence of other common infectious agents, and the dramatic response to antiviral therapy, after the failure of previous antibiotic and antifungal treatments. Rather unusual clinical features of this patient include the early occurrence of the disease, that is, during the first phase of induction treatment, the apparent absence of mucocutaneous lesions on physical examination, the persistent absence of fever, and the paucity of respiratory symptoms, at onset and during the initial course of the disease. All the clinical features, mentioned above, should alert clinicians on the possibly smouldering presentation of HSV-1 pneumonia in leukemic patients. Since HSV pneumonia is potentially fatal, a prompt treatment with acyclovir may be the only chance for such patients to achieve a successful outcome. Multiple myeloma (MM) is a clonal malignant plasma cell disorder characterized by the accumulation of malignant cells within the bone marrow, leading to lytic bone lesions and medullary insufficiency. Despite recent advances in the management of patients with MM (high-dose chemotherapy, thalidomide and derivatives, proteasome inhibitors), the disease remains ultimately lethal within variable periods of time, ranging from a few weeks to more than 10 years. Thus, novel therapeutic approaches are highly warranted.
In the past few years, several monoclonal antibodies have been shown to present therapeutic activities in a broad range of malignancies, either for hematological malignancies or for solid tumors. One of the best examples is the rapid positioning of rituximab in the therapeutic armamentarium of CD20-positive hemopathies. Thus, the search of novel potential therapeutic targets on cell surface of malignant cells is a major objective in clinical research. For instance, we have recently shown that CD20 was expressed at the surface of malignant plasma cells of 10-15% of MM, 1 leading to an ongoing prospective therapeutic trial using rituximab.
In a systematic examination of such potential targets in MM, we conducted an expertise of the expression of CD33 on plasma cells. CD33 is usually expressed in the myeloid lineage (but not in the B-cell lineage), 2 and has been targeted by monoclonal antibodies coupled with calicheamycin (gemtuzumab ozogamicin, Mylotarg s , Wyeth, Philadelphia). This modified antibody is now used in the treatment of patients with acute myeloid leukemia (AML) who express CD33 in more than 90% of the cases, with encouraging results. 3 We studied the expression of CD33 on bone marrow plasma cells of 65 consecutive patients with MM analyzed between December 2003 and December 2004, and on 16 human myeloma cell lines. In four patients, two samples could be analyzed, one at diagnosis and a second one at relapse. All the 69 patient bone marrow specimens were centrifuged (FicollHypaque) before labeling with the following antibodies: anti-CD45-FITC (J33), anti-CD138-PECy5 (B-B4), anti-CD38-APC (HB7), and with control-PE or anti-CD33-PE (P67.6) in a fourcolor assay. Labeled cells were then analyzed on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), with the CellQuest Pro software (BD Biosciences). Plasma cells were identified using a sequential gating strategy as previously described. 1 The following human myeloma cell lines have been analyzed: RPMI-8226, NCI-H929, JJN3, OPM2, U266, JIM3, KMS11, L363, MDN, NAN3, NAN4, SBN, XG1, XG2, XG6, and LP1.
CD33 was detected on plasma cells in 23 of the 65 patients with MM (35%) and in four of the 16 myeloma cell lines (25%). When detected, it was expressed on 11-100% of the malignant plasma cells (median ¼ 54%) (Figure 1 ). The positivity cutoff was arbitrarily fixed at 50%. With this cutoff, 14 patients and three cell lines (RPMI-8226, NAN-4, and XG2) were positive, with a median percentage of CD33-positive plasma cells of 85% (range ¼ 50-100%) ( Table 1 ). Three of these 14 patients have been analyzed twice (at diagnosis and at early relapse), and similar CD33 expression was observed. CD33 expression is restricted to malignant plasma cells (not or slightly expressed on normal bone marrow plasma cells, data not shown). A similar incidence of CD33 expression has been previously reported in MM. 4, 5 In CD33-positive patients, the median ratio of fluorescence intensity (RFI) was 14 (range ¼ 6. . When compared to CD33-positive AML, the median MM RFI was equivalent
